RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

Core Insights - RenovoRx, Inc. is advancing its innovative targeted oncology therapies through the RenovoCath device, which has received FDA clearance for drug delivery [1][7] - New clinical data will be presented at the 2026 Society of Interventional Oncology Annual Scientific Meeting, focusing on optimizing drug delivery in solid tumors using the TAMP therapy platform [1][2] Clinical Study Findings - The study titled "Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors" aims to simplify intra-arterial pressure measurement during TAMP procedures [2][4] - Real-time pressure measurements provide insights into the mechanics of TAMP procedures, potentially enhancing drug delivery effectiveness [3][4] - The study demonstrates that an external pressure transducer can reliably measure intra-arterial pressure, correlating well with intravascular pressure wire measurements [3] Presentation Details - The clinical data will be presented on February 6, 2026, at 5:45-6:00 PM ET, with the abstract number 303 [4] Company Overview - RenovoRx is focused on developing targeted therapies for high unmet medical needs, utilizing the TAMP therapy platform to minimize toxicities compared to systemic therapies [7] - The company is in the early stages of commercializing the RenovoCath device, having generated approximately $900,000 in revenue from sales in the first nine months of 2025 [8] Product Development - RenovoRx is evaluating a novel drug-device combination candidate, IAG, which involves intra-arterial delivery of gemcitabine via RenovoCath, currently in Phase III trials [9][10] - IAG has received Orphan Drug Designation for pancreatic and bile duct cancers, granting seven years of market exclusivity upon FDA approval [10]